tbuckley/cabot-search huggingface dataset:
Pegylated interferon modulates innate immunity in eAg positive chronic hepatitis B and determines changes in HBsAg quantification
Authors: U. Gill, L. Micco, L. Li, D. Peppa, I. Ushiro-Lumb, G. R. Foster, M. K. Maini, P. T. F. Kennedy
Journal: Gut (2011)

<h3>Introduction</h3> Pegylated-Interferon a (PEG-IFNα) therapy provides sustained immune control and is associated with HBsAg loss and improved survival. Despite this, the immune mechanisms and timing of immunomodulatory effects remain ill-defined. Recent data has reported changes in a subset of NK cells in HBeAg negative disease which may predict response. This study evaluated the effects of PEG-IFNα on the innate immune response in eAg positive patients, a cohort known to respond favourably to interferon. <h3>Methods</h3> Paired PBMC samples were compared pre and during PEG-IFNα therapy from 16 patients. Changes in innate immune responses were evaluated at two on-treatment intervals, 12 and 24 weeks. The number, phenotype and function of NK cell populations were assessed. The expression of TNF related apoptosis inducing ligand (TRAIL) and the production of interferon γ (IFNγ) on the NK cell population was determined with flow cytometry. Changes in the innate response were correlated with HBsAg quantification (Abbott ARCHITECT). <h3>Results</h3> PEG-IFNα increased the CD56<sup>bright</sup> NK cell population (CD56/CD16) by threefold (mean fold change; MFC 3.02, p=0.01) in all patients. This was associated with an overall decline in HBsAg 0.42 log and HBV DNA 2.5 log. Further increase in CD56<sup>bright</sup> NK cells was noted from 12 to 24 weeks (MFC 2.3 vs 3.7). Consistent with this, HBsAg decline was also more marked at 24 weeks (mean decline log 0.13 vs 0.70). In the absence of HBsAg decline, there was no upregulation of CD56<sup>bright</sup> NK cells. Upregulation of TRAIL expression was noted on this CD56<sup>bright</sup> NK subset by more than twofold (MFC 2.44, p=0.009), this effect was more dramatic at 12 weeks (MFC 2.12 vs 2.72). A twofold increase in IFNγ producing CD56<sup>bright</sup> NK cells was observed, (MFC 2.39, p=0.03); again this effect was more marked at 12 weeks (MFC 2.61 vs 2.01). <h3>Conclusion</h3> These data highlight the effects of PEG-IFNα on the innate immune response in eAg positive CHB. An upregulation of CD56<sup>bright</sup> NK cells, their expression of TRAIL and IFNγ production presage a decline in HBsAg and HBV DNA. These changes observed at 12 weeks, are not reflected in concurrent HBsAg decline, but may predict sustained immune control in the longer term with a more marked HBsAg decline at 24 weeks.
Sensitivity of Lymphocytes from Vulcanizers to the in Vitro Induction of Sister Chromatid Exchanges
Authors: F. Degrassi, R. De Salvia, M. Fiore, R. Ricordy, C. Tanzarella, R. Benigni, F. Palitti
Journal: Environmental Health Perspectives (1993)

Spontaneous frequencies of sister chromatid exchanges (SCEs) and SCEs induced in vitro by chemicals with different mechanisms of action such as mytomycin C, 4-nitroquinoline oxide, and 3-aminobenzamide were examined in phytohemagglutinin-stimulated peripheral blood lymphocytes from a group of workers in a rubber plant and a control group, both of which had been analyzed for levels of spontaneous SCEs 2 years earlier.An interindividual variability in the induction of SCEs was found after in vitro treatments with the different mutagens, which did not correlate with occupational exposure.This variability in the sensitivity to the induction of SCEs might be correlated to genetic differences among individuals, which have to be taken into account in environmental monitoring programs.
THE PRESIDENT'S ADDRESS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Occupational scabies.
Authors: R J Rycroft, C D Calnan
Journal: BMJ (1977)

A localised epidemic of scabies lasting nearly a year occurred among crews on river pleasure craft. There was a sharp contrast between the paucity of scabietic lesions, especially burrows, and an unusually high infectivity. Scarcely a crew member was free from itching, yet individually diagnosis proved extremely difficult.
International Clinics. A quarterly of clinical lectures on Medicine, Neurology, Surgery, Gynecology, Obstetrics, Ophthalmology, Laryngology, Pharyngology, Rhinology, Otology and Dermatology, and specially prepared articles on treatment, by professors and lecturers in the leading medical colleges of the United States, Germany, Austria, France, Great Britain and Canada.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thrombocytopenia During Interferon Alfa Therapy
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
History of Hospitals
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOKS RECEIVED
Journal: British Journal of Dermatology (1924)

British Journal of DermatologyVolume 36, Issue 12 p. 578-578 BOOKS RECEIVED First published: December 1924 https://doi.org/10.1111/j.1365-2133.1924.tb09157.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Artificial Sunlight and its Therapeutic Uses. By F. H. Humphris, M.D. Brux., F.R.C.P. Edin. Ultra-Violet Rays in the Treatment and Cure of Disease. By P. Hall, M.R.C.S. Handbuch der Salvarsantherapie. By W. Kolle and K. Zieler. Die Beziehungen der genitalorgaue zu Hautveränderungen. By Dr. Kurt Wiener. Der Ausfall des Kopfhaars und seine Behandlung. By Dr. Felix Pinkus. Beziehungen der ekzematösen Erkranhungen zu inneren Leiden. By Dr. S. Ehrmann. Volume36, Issue12December 1924Pages 578-578 RelatedInformation
The operation of a radiology consultation service in an acute care hospital
Authors: S. R. Baker
Journal: JAMA (1982)

The operation of a radiology consultation service in an acute care teaching hospital is described. The radiologist acts as an active advisor in the structuring of diagnostic evaluations in three disease categories; biliary tract disease, nonemergency gastrointestinal tract bleeding, and abdominal mass. There was a 64% reduction in the time needed to establish a diagnosis and a 32% decrease in the number of studies for each patient on the consultation ward compared with a control group, which consisted of patients with similar clinical presentations. A formal partnership between clinician and radiologist serves two important functions in teaching hospitals. It can simultaneously expedite diagnostic evaluations and teach the best utilization of imaging examinations. (<i>JAMA</i>1982;248:2152-2154)
Detection of neurological damage during open-heart surgery
Authors: M. A. Branthwaite
Journal: Thorax (1973)

<b>Branthwaite, M. A. (1973).</b><i>Thorax,</i><b>28,</b> 464-472. <b>Detection of neurological damage during open-heart surgery.</b> Cerebral activity during open-heart surgery has been recorded in 140 patients using a heavily filtered electroencephalograph, the Cerebral Function Monitor (CFM). Unlike the conventional electroencephalogram the CFM record is recorded at slow speeds, is filtered to minimize electrical interference, and is easy to interpret. A high incidence (62·9%) of alteration in electrical activity was noted at the onset of perfusion, and several different patterns of change are described. Ten patients suffered neurological damage to a degree which produced physical signs in the postoperative period. In eight of these 10 cases, abnormal depression of the CFM record was noted during perfusion; the depression occurred at the onset on five occasions. Equivocal changes were noted at the onset of perfusion in one patient whose neurological lesion may have been related to a postoperative cardiac rhythm disorder. One patient sustained a midbrain lesion, probably at the onset of perfusion, and the CFM record during operation was unremarkable. The incidence of both neurological damage and depression of the CFM record at the onset of perfusion has decreased since filters for microemboli have been included in the perfusion circuit. It is concluded that the CFM is a useful means of detecting acute changes in cortical activity during open-heart surgery. The risk of cerebral damage is high at the onset of perfusion when both hypotension and microemboli from the extracorporeal circuit may contribute to the neurological lesion.
Scleroderma of the Esophagus: A Correlation of Histologic and Physiologic Findings
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) - final results of a British Thoracic Oncology Group (BTOG) trial
Authors: P. Lorigan, R. Booton, L. Ashcroft, K. O'Byrne, H. Anderson, M. Nicolson, P. A. Burt, C. Faivre-Finn, N. Thatcher
Journal: Journal of Clinical Oncology (2004)

7066
NERVE CONDUCTION IN VITAMIN B12 DEFICIENCY
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fear
Authors: Saty Satya-Murti
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quality Assurance for Office Laboratories-Reply
Authors: Daniel M. Baer
Journal: JAMA (1986)

<h3>In Reply.—</h3> We are sorry for the omission of Fisher Scientific from the product and manufacturer lists in our article. We endeavored to provide as much information as we could collect to allow readers to identify systems and suppliers of interest easily. In developing the tables listing products, distributors, and manufacturers of office laboratory systems and supplies, we talked to innumerable sales representatives, including some from Fisher Scientific, over an 18-month period. Some manufacturers and distributors learned that we were interested in this information and began sending announcements and other product information without solicitation. During the collection process, we noted that many sales representatives were unaware of office laboratory products being offered by their companies. We therefore also called national sales offices attempting to secure information about their products. Occasionally the only response to our inquiries was the receipt of a 1000-to 1500-page general laboratory catalog including, presumably, products appropriate
A phase II, multi-center study of a new non-cytotoxic A3 adenosine receptor agonist CF101, dose-finding (randomized blinded) in patients (pts)with refractory metastatic colorectal cancer
Authors: S. M. Stemmer, A. Shani, B. Klein, M. H. Silverman, I. Lorber, M. Farbstein, E. Shmueli, A. Figer
Journal: Journal of Clinical Oncology (2004)

3153 Background:The A3 adenosine Gi protein-coupled receptor is highly expressed in malignant compared to normal cells. Activating the A3 adenosine receptor (A3AR) with the highly selective non-cytotoxic agonist, CF101 (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-β-D-ibofuronamide, IB-MECA), induces growth inhibition of colon carcinoma and other tumor cell types via down-regulation of the Wnt and NF-κB related pathways. Oral CF101 has been shown to inhibit human colon and prostate cancer growth in nude mice. A Phase I study in healthy volunteers showed that CF101 at doses up to 4 mg PO BID, produced no drug-related toxicity with linear pharmacokinetics and good bioavailability. Methods: A phase II dose finding, randomized, blinded study of oral CF101 (0.1, 1 & 4 mg PO BID) was conducted to define activity and safety in a heavily pre-treated metastatic colorectal cancer pts. From 6/1/2003–12/1/2003, 61 pts (25 F, 36 M), median age 61 (range 30–83) with measurable colorectal cancer, PS ≤2 were enrolled. 14 pts progressed after irinotecan and 47 pts after both irinotecan and oxaliplatin-based regimens. The study is still ongoing. Results: By 12/1/2003, 46 pts completed at least 8 weeks (W) of treatment or were withdrawn due to disease progression. The median time on treatment was 8.7W (1–19.7+). PR/CR was not observed; however, SD for at least 8W duration was achieved in 16 pts (35%). Three pts are still on treatment without disease progression after 16W. Four pts died within 8W of treatment (2, 3, 4 & 1W). Two of these pts were found to be ineligible, were removed from study and died of PD. One patient deteriorated due to PD while on study and was withdrawn from treatment prior to death. The forth, died suddenly while on study. In the other pts, there were no obvious treatment related serious adverse events. Conclusions: The interim blinded results from this ongoing study, shows that CF101 appears to be well tolerated and may stabilize disease for at least 2 months in 35% of the pts. The data justifies a continued investigation of CF101 in the treatment of refractory metastatic colorectal cancer. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Can-Fite BioPharma
Calcium Metabolism and Calcium Therapy.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Plague pneumonia--California
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal